Exobiosphere, a Luxembourg-based space biotech company, has secured €1 million in non-dilutive funding from the country’s Jeune Entreprise Innovante (JEI) aid scheme. The grant will support the startup’s commercial expansion efforts and help scale its proprietary orbital high-throughput screening platform for drug discovery applications in microgravity environments.
The funding represents a significant milestone for the recently established company, which was founded in 2024. According to the startup, the capital will be deployed across multiple areas of its operations, including strengthening internal teams, expanding commercial activities, growing international business development and marketing initiatives, and advancing the technological capabilities of its orbital screening system.
Accelerating a Novel Drug Discovery Approach
Exobiosphere’s platform leverages microgravity conditions in orbit to conduct high-throughput screening—a process used by pharmaceutical and biotech companies to test thousands of potential drug compounds rapidly. The unique environment of space offers distinct advantages for certain types of biological research and drug development activities, presenting an emerging frontier in the healthtech sector.
Kyle Acierno, a company representative, commented on the significance of the award. “This grant lands at exactly the right moment and makes a real difference for a company at our stage,” he stated. “It allows us to expand our commercial activities, strengthen our team, and bring our technological offer to more pharmaceutical and biotech partners around the world. We’re grateful for the continued support of the Luxembourg innovation ecosystem and Ministry of Economy.”
Tapping into Luxembourg’s Innovation Support
The JEI programme is part of Luxembourg’s broader strategy to nurture innovative enterprises and strengthen its position as a hub for emerging technologies. By offering non-dilutive funding—which does not require the company to surrender equity—the scheme enables startups to retain full ownership while accessing capital for growth initiatives.
The grant allocation underscores Luxembourg’s strategic focus on space technology and life sciences sectors. The Grand Duchy has positioned itself as a center for space innovation and has cultivated a supportive regulatory and financial environment for companies operating in adjacent sectors, including space biotech and orbital manufacturing.
Broader European Context
The funding announcement reflects broader European efforts to develop competitive advantages in space-based research and development. As companies across the continent explore novel applications of microgravity environments—ranging from materials science to pharmaceutical development—governments and regional bodies are increasingly backing initiatives that combine space access with life sciences innovation.
Exobiosphere’s progress demonstrates growing interest among European entrepreneurs in leveraging orbital infrastructure for commercial drug discovery applications. The startup’s expansion plans signal confidence in the viability of space-based screening platforms as a differentiated offering to the global pharmaceutical industry, positioning Luxembourg as a potential player in this emerging niche sector.